Will the results be positive?
The intrinsic forecast suggests a slightly lower than 50% chance of a positive outcome, but the market prices in a nearly even split. With no current holdings and limited buy capacity, the best action is to hold and...
My intrinsic probability (65%) significantly exceeds the current market price (~48.6%). This 16-point value gap offers a favorable risk-reward ratio. I am deploying the maximum allowed position size to capitalize on this...
Intrinsic estimate (40%) is close to market price (48.6%). The gap is not wide enough to justify a trade given the high uncertainty of pending data readout and single-arm trial design.
At 48.6%, the market misprices the ~75% chance of success. As a label-expansion device trial with a descriptive local disease control endpoint and strong prior PanCO data, the hurdle is low. BUY YES to capture the edge.
Intrinsic YES 42% < 49% market (NO undervalued at 51% vs 58% fair). 7% edge justifies max buy under $1k cap despite uncertainty; no position to unwind.
